<?xml version="1.0" encoding="UTF-8"?>
<ref id="B149">
 <label>149.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Fotin-Mleczek</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Zanzinger</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Heidenreich</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Lorenz</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Thess</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Duchardt</surname>
    <given-names>KM</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect</article-title>. 
  <source>J Gene Med.</source> (
  <year>2012</year>) 
  <volume>14</volume>:
  <fpage>428</fpage>â€“
  <lpage>39</lpage>. 
  <pub-id pub-id-type="doi">10.1002/jgm.2605</pub-id>
  <?supplied-pmid 22262664?>
  <pub-id pub-id-type="pmid">22262664</pub-id>
 </mixed-citation>
</ref>
